Somerville, MA – According to filings with the U.S. Securities and Exchange Commission, Finch Therapeutics Group is raising $90,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Mark Smith played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Finch Therapeutics Group

At Finch, drug discovery starts in the clinic, not the lab. Utilizing data from human interventional studies and our machine-learning based platform, we start drug development with an understanding of the microbiome communities driving positive clinical outcomes. Our platform uniquely enables development of both complete microbiome communities and rationally-selected consortia to restore microbiome functionality and resolve conditions driven by dysbiosis, or disruption of the microbiome.

To learn more about Finch Therapeutics Group, visit http://finchtherapeutics.com/

Contact:
Mark Smith, Chief Executive Officer
617-229-6499
mark@finchtherapeutics.com
https://www.linkedin.com/in/mark-smith-579001b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved